SAM #NOI-OD-26-000038

Sole Source Procurement of Compounded IV Narcotics from QuVa Pharma, Inc. for NIH Clinical Center

The National Institutes of Health (NIH) Clinical Center Pharmacy Department is planning a sole source procurement for compounded intravenous (IV) narcotics to support patient care and clinical research protocols. - Government Buyer: - Department of Health and Human Services (HHS), National Institutes of Health (NIH), Clinical Center, Pharmacy Department, Pharmaceutical Procurement Section - OEM and Vendor: - QuVa Pharma, Inc. is the exclusive manufacturer and distributor of the required 503b compounded IV narcotics in the United States - Products/Services Requested: - Compounded intravenous (IV) narcotics for patient care - No specific part numbers or quantities provided - Contract Details: - Blanket purchase agreement with a base year and four optional years - Total estimated contract value: $684,000 - Unique/Notable Requirements: - Sole source justification due to QuVa Pharma, Inc. being the only authorized manufacturer and distributor for these products in the U.S. - Supports patient care under human research protocols at a clinical research hospital - Place of Performance: - NIH Clinical Center, Bethesda, Maryland

Description

The purpose of this acquisition is to purchase 503b compounded Intravenous (IV) Narcotics for patient care. Market research has been conducted with only two responses, from QUVA, the known Compounder and distributor for these IV narcotics.  Through trade shows, continuous learning seminars and trade journals, the CC Pharmacy Department stays abreast of the industry and is current on the availability of singular distribution outlets for these medications.

•             Product Service Code: 6515 – Medical and Surgical Instruments, Equipment, and Supplies

•             NAICS Code: 325412 – Pharmaceutical Preparation Manufacturing

•             Place of Performance: NIH Clinical Center, Bethesda, MD 20892 USA

POTS: 26-000038

Description:

This is a notice of intent, not a request for a quotation.  A solicitation document will not be issued, and quotations will not be requested.

The National Institutes of Health (NIH) intends to award a one-year contract to QuVa Pharma, Inc., located at 3 Sugar Creek Center Boulevard, Sugarland, TX 77478, on a firm fixed price sole source award basis for the purchase of 503b compound Intravenous (IV) Narcotics for patient care.

The proposed vendor, QuVa Pharma Inc., is the Original Manufacturer and has not designated other distributors of IV narcotics in the U.S.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.  Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Huda Malik, Contract Specialist via email to huda.malik@nih.gov by May 6, 2026 at 9 am EST.

View original listing